Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-876-8191
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$230,000.00
Profitability
Miscellaneous
Employees61
Next Earnings Date10/24/2019 (Confirmed)
OptionableOptionable
Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences Inc (NASDAQ:GNCA) announced its quarterly earnings data on Thursday, July, 25th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.02. View Genocea Biosciences' Earnings History.
When is Genocea Biosciences' next earnings date?
How can I listen to Genocea Biosciences' earnings call?
Genocea Biosciences will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for GNCA?
3 brokerages have issued 1-year price targets for Genocea Biosciences' shares. Their forecasts range from $16.00 to $32.00. On average, they expect Genocea Biosciences' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 823.1% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.
What is the consensus analysts' recommendation for Genocea Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.
What are Wall Street analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (9/25/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are lowering our price target to $32 from $42 to reflect the recent dilution, and fully diluted share count from the company’s equity raise." (7/25/2019)
Has Genocea Biosciences been receiving favorable news coverage?
Media headlines about GNCA stock have trended very positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genocea Biosciences earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Genocea Biosciences.
Are investors shorting Genocea Biosciences?
Genocea Biosciences saw a decrease in short interest in September. As of September 30th, there was short interest totalling 178,400 shares, a decrease of 8.3% from the August 30th total of 194,500 shares. Based on an average trading volume of 148,300 shares, the short-interest ratio is currently 1.2 days. Currently, 1.2% of the shares of the company are short sold. View Genocea Biosciences' Current Options Chain.
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include PDL BioPharma (PDLI), Scholar Rock (SRRK), ADMA Biologics (ADMA), BioCryst Pharmaceuticals (BCRX), Eiger Biopharmaceuticals (EIGR), La Jolla Pharmaceutical (LJPC), Sutro Biopharma (STRO), LogicBio Therapeutics (LOGC), Compugen (CGEN), Dyadic International (DYAI), Oncobiologics (ONS), X4 Pharmaceuticals (XFOR), Allena Pharmaceuticals (ALNA), Axcella Health (AXLA) and Gamida Cell (GMDA).
What other stocks do shareholders of Genocea Biosciences own?
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)
- Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)
- Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)
- Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)
- Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55)
How do I buy shares of Genocea Biosciences?
Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of GNCA stock can currently be purchased for approximately $2.60.
How big of a company is Genocea Biosciences?
Genocea Biosciences has a market capitalization of $67.99 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.View Additional Information About Genocea Biosciences.
What is Genocea Biosciences' official website?
How can I contact Genocea Biosciences?
Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]
MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
